Use the Back button in your browser to see the other results of your search or to select another record.

Detailed Search Results

Do metronomes improve the quality of life in people with Parkinson's disease? A pragmatic, single-blind, randomized cross-over trial [with consumer summary]
Elston J, Honan W, Powell R, Gormley J, Stein K
Clinical Rehabilitation 2010 Jun;24(6):523-532
clinical trial
4/10 [Eligibility criteria: Yes; Random allocation: Yes; Concealed allocation: Yes; Baseline comparability: No; Blind subjects: No; Blind therapists: No; Blind assessors: No; Adequate follow-up: No; Intention-to-treat analysis: No; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*

OBJECTIVE: To evaluate the effect of acoustic cueing using metronomes on the quality of life of people with moderate to severe Parkinson's disease. STUDY DESIGN: Pragmatic, single-blind, randomized cross-over trial. PARTICIPANTS: Forty-two people aged 50 to 85 years, in Hoehn and Yahr stage II to IV and on stable medication. Eight were lost to follow-up. INTERVENTION: Participants were randomized using concealed allocation to either an early group (n = 21) to receive an electronic metronome without therapy but limited support (5 to 10 minutes instruction and on-demand telephone assistance) for four weeks, or a late group (n = 21) to receive the same intervention at 10 weeks. In both groups the beat frequency was initially set to be comfortable for walking. OUTCOMES MEASURES: Primary and secondary outcomes were measured at baseline, 4, 10 and 14 weeks using the Parkinson's Disease Questionnaire 39 (PDQ-39), the Short Form 36 version 2 (SF-36 version 2) and a falls diary. RESULTS: There were positive effects in six domains of the SF-36 version 2 and eight domains of the PDQ-39, although only one mean difference was clinically important: the role limitation (emotional) domain of SF-36 version 2 (a mean difference of 3.77, 95% confidence interval (CI) -2.68 to 10.22), a secondary outcome. None of these changes were statistically significant. There were no statistically significant differences in falls rates over the study period. Ten participants (24%) wanted to continue with their metronomes at the end of the study. CONCLUSION: To demonstrate metronomes are beneficial on the role limitation domain of the SF-36 version 2 in people with moderate to severe Parkinson's disease a sample size of 600 would be required.

Full text (sometimes free) may be available at these link(s):      help